Results 11 to 20 of about 19,553 (185)
Nanobodies that Neutralize HIV [PDF]
Vaccines, 2019 Nanobodies or VHH (variable domains of heavy-chain only antibodies) are derived from camelid species such as llamas and camels. Nanobodies isolated and selected through phage display can neutralize a broad range of human immunodeficiency virus type 1 ...
Robin A. Weiss, C. Theo Verrips
doaj +3 more sources
Nanobody based dual specific CARs [PDF]
International Journal of Molecular Sciences, 2018 Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas.
Abken, Hinrich +8 more
core +6 more sources
Structure of Nanobody Nb23 [PDF]
Molecules, 2021 Background: Nanobodies, or VHHs, are derived from heavy chain-only antibodies (hcAbs) found in camelids. They overcome some of the inherent limitations of monoclonal antibodies (mAbs) and derivatives thereof, due to their smaller molecular size and higher stability, and thus present an alternative to mAbs for therapeutic use.
Percipalle M. +4 more
openaire +5 more sources
Seminars in Immunology, 2021 For treatment and diagnosis of cancer, antibodies have proven their value and now serve as a first line of therapy for certain cancers. A unique class of antibody fragments called nanobodies, derived from camelid heavy chain-only antibodies, are gaining increasing acceptance as diagnostic tools and are considered also as building blocks for chimeric ...
Elisha R, Verhaar +2 more
openaire +3 more sources
Antibodies, 2020 Since their first description in 1993 [...]
Patrick Chames, Ulrich Rothbauer
openaire +3 more sources
Microorganisms, 2021 Nanobodies are camelid-derived single-domain antibodies that present some advantages versus conventional antibodies, such as a smaller size, and higher tissue penetrability, stability, and hydrophilicity. Although nanobodies can be delivered as proteins,
Noelia Silva-Pilipich +2 more
doaj +1 more source
Nanobody: a promising toolkit for molecular imaging and disease therapy
EJNMMI Research, 2021 Nanobodies are the recombinant variable domains of heavy-chain-only antibodies, with many unique properties such as small size, excellent solubility, superior stability, quick clearance from blood, and deep tissue penetration.
Guangfa Bao +3 more
doaj +1 more source
Immunogenicity Risk Profile of Nanobodies [PDF]
Frontiers in Immunology, 2021 Nanobodies (Nbs), the variable domains of camelid heavy chain-only antibodies, are a promising class of therapeutics or in vivo imaging reagents entering the clinic. They possess unique characteristics, including a minimal size, providing fast pharmacokinetics, high-target specificity, and an affinity in the (sub-)nanomolar range in conjunction with an
Chloé Ackaert +17 more
openaire +5 more sources
Electrochemical detection of Toxocara canis excretory-secretory antigens in children from rural communities in Esmeraldas Province, Ecuador: association between active infection and high eosinophilia. [PDF]
, 2020 BACKGROUND: The diagnosis of active Toxocara canis infections in humans is challenging. Larval stages of T. canis do not replicate in human tissues and disease may result from infection with a single T. canis larva.
Chico, M +9 more
core +3 more sources
Nanobody-Targeted Photodynamic Therapy: Nanobody Production and Purification
, 2022 Nanobodies have recently been introduced to the field of photodynamic therapy (PDT) as a very promising strategy to target photosensitizers selectively to cancer cells. Nanobodies are known for their characteristic small size (15 kDa), high specificity, and high binding affinities.
Mashayekhi, Vida +4 more
openaire +4 more sources